🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are escalating globally, with figures suggesting over 82 million instances per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

According to findings released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The research included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals on the front lines have shared positive views. Having a easy-to-administer therapy of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.